News
Funding for Zucara Therapeutics Expansion Into ZT-01 Development Program to Type 2 Diabetes
November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations, announced today that it has received funding from NRC IRAP and MITAS for its expansion into the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”).
Red more here: https://bit.ly/34QRAn6
Read more
Bristol Myers Squibb Enters Agreement to Acquire Forbius
TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio.
TIAP was one of the earliest investors and partners with Forbius in 2011/12. This is a big win for Forbius CEO Dr. Tikhomirov and the Canadian research and innovation community. Forbius (formerly Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic ...
Read more
LAB150 launches new immuno-oncology project from Sunnybrook Research Institute
Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his lab at Sunnybrook Research Institute, a TIAP Member institution.
The last several years has seen the introduction of a new blockbuster class of drugs for treating cancers – specifically, the immune checkpoint inhibitors (ICIs). These drugs act ...
Read more
Funding for Sinai Health Netherton Syndrome project from partners AmorChem and Evotec
TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.
The project was initiated in partnership with a group of scientists from Sinai Health’s Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins. These proteins ...
Read more
Zucara Therapeutics Announces US$21M Series A Financing
– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials –
– Series A Financing led by the Perceptive Xontogeny Venture Fund –
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”).
The proceeds from the financing will fund Phase 1 and ...
Read more
TIAP Announces New President and CEO
Toronto, Ontario, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of TIAP – Toronto Innovation Acceleration Partners (formerly MaRS Innovation) – is pleased to announce the appointment of Parimal Nathwani as TIAP’s new President and Chief Executive Officer effective April 1, 2020. Nathwani succeeds Dr. Raphael Hofstein who has served as the organization’s leader since 2009.
Parimal Nathwani, who currently serves as TIAP’s Vice President, has been with the organization since its inception in 2009 and has been fundamental to ...
Read more
Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis
Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor.
Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ...
Read more
Allogene Therapeutics enters collaboration with Notch Therapeutics
Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma
Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales
SOUTH SAN FRANCISCO, Calif. and TORONTO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic ...
Read more
Zealand Pharma Acquires Encycle Therapeutics
Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a pre-clinical, orally-delivered macrocycle peptide (integrin alpha-4-beta-7 inhibitor). Encycle is founded on research coming from University of Toronto - a TIAP member institution. Read more here: http://bit.ly/2W2hH4N
Read more
TIAP Enters Partnership to Establish Venture Capital Fund
TIAP and DAYLI Partners, a leading biotech venture caital firm in South Korea, are collaborating on the creation of a new venture capital fund focused on biotech and health sciences in Canada. The joint investment team will identify & invest in seed stage companies primarily in Ontario with a portion of the fund allocated to Korean companies with high potential to expand to Ontario. Read more here: http://bit.ly/35FH40K
Read more